Revelation in the neuroprotective functions of rasagiline and selegiline: the induction of distinct genes by different mechanisms

References

• Forno LS. Neuropathology of Parkinson’s disease. J. Neuropathol. Exp. Neurol. 55(3), 259–272 (1996).
   PubMed Web of Science ®Google Scholar
• Dauer W, Przedborski S. Parkinson’s disease: mechanisms and models. Neuron 39(6), 889–909 (2003).
   PubMed Web of Science ®Google Scholar
• Thomas B, Beal MF. Parkinson’s disease. Hum. Mol. Genet. 16 Spec No. 2, R183–R194 (2007).
   PubMed Web of Science ®Google Scholar
• Cookson MR, Bandmann O. Parkinson’s disease: insights from pathways. Hum. Mol. Genet. 19(R1), R21–R27 (2010).
   PubMed Web of Science ®Google Scholar
• Bossy-Wetzel E, Schwarzenbacher R, Lipton SA. Molecular pathways to neurodegeneration. Nat. Med. 10(Suppl.), S2–S9 (2004).
   PubMed Web of Science ®Google Scholar
• Jenner P, Olanow CW. The pathogenesis of cell death in Parkinson’s disease. Neurology 66(10 Suppl. 4), S24–S36 (2006).
   PubMed Web of Science ®Google Scholar
• Mosley RL, Benner EJ, Kadiu I et al. Neuroinflammation, oxidative stress and the pathogenesis of Parkinson’s disease. Clin. Neurosci. Res. 6(5), 261–281 (2006).
   PubMed Web of Science ®Google Scholar
• Trushina E, McMurray CT. Oxidative stress and mitochondrial dysfunction in neurodegenerative diseases. Neuroscience 145(4), 1233–1248 (2007).
   PubMed Web of Science ®Google Scholar
• Levy OA, Malagelada C, Greene LA. Cell death pathways in Parkinson’s disease: proximal triggers, distal effectors, and final steps. Apoptosis 14(4), 478–500 (2009).
   PubMed Web of Science ®Google Scholar
• Riederer PF. Views on neurodegeneration as a basis for neuroprotective strategies. Med. Sci. Monit. 10, RA287–RA290 (2004).
   PubMed Web of Science ®Google Scholar
• Clarke PG. Developmental cell death: morphological diversity and multiple mechanisms. Anat. Embryol. 181(3), 195–213 (1990).
   PubMedGoogle Scholar
• Alves da Costa C, Checler F. Apoptosis in Parkinson’s disease: is p53 the missing link between genetic and sporadic Parkinsonism? Cell. Signal. 23(6), 963–968 (2011).
   PubMed Web of Science ®Google Scholar
• Mochizuki H, Nishi K, Mizuno Y. Iron–melanin complex is toxic to dopaminergic neurons in a nigrostriatal co-culture. Neurodegeneration 2, 1–7 (1993).
   Google Scholar
• Pan T, Kondo S, Le W, Jankovic J. The role of autophagy–lysosome pathway in neurodegeneration associated with Parkinson’s disease. Brain 131(Pt 8), 1969–1978 (2008).
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Mochizuki H, Sugita Y, Goto K. Apoptosis in neurodegenerative disorders. Intern. Med. 37(2), 192–193 (1998).
   PubMed Web of Science ®Google Scholar
• Jellinger KA. Cell death mechanisms in neurodegeneration. J. Cell. Mol. Med. 5(1), 1–17 (2001).
   PubMed Web of Science ®Google Scholar
• Tatton WG, Chalmers-Redman R, Brown D, Tatton N. Apoptosis in Parkinson’s disease: signals for neuronal degradation. Ann. Neurol. 53(Suppl. 3), S61–S70; discussion S70 (2003).
   PubMed Web of Science ®Google Scholar
• Simunovic F, Yi M, Wang Y et al. Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology. Brain 132(Pt 7), 1795–1809 (2009).
   PubMed Web of Science ®Google Scholar
• Anglade P, Vyas S, Javoy-Agid F et al. Apoptosis and autophagy in nigral neurons of patients with Parkinson’s disease. Histol. Histopathol. 12(1), 25–31 (1997).
   PubMed Web of Science ®Google Scholar
• Reed JC. Apoptosis-based therapies. Nat. Rev. Drug Discov. 1(2), 111–121 (2002).
   PubMed Web of Science ®Google Scholar
• Vila M, Przedborski S. Targeting programmed cell death in neurodegenerative diseases. Nat. Rev. Neurosci. 4(5), 365–375 (2003).
   PubMed Web of Science ®Google Scholar
• Fischer U, Schulze-Osthoff K. New approaches and therapeutics targeting apoptosis in disease. Pharmacol. Rev. 57(2), 187–215 (2005).
   PubMed Web of Science ®Google Scholar
• Schapira AH, Bezard E, Brotchie J et al. Novel pharmacological targets for the treatment of Parkinson’s disease. Nat. Rev. Drug Discov. 5(10), 845–854 (2006).
   PubMed Web of Science ®Google Scholar
• Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Protection against the dopaminergic neurotoxicity of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase inhibitors. Nature 311(5985), 467–469 (1984).
   PubMed Web of Science ®Google Scholar
• Finberg JP, Takeshima T, Johnston JM, Commissiong JW. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. Neuroreport 9(4), 703–707 (1998).
   PubMed Web of Science ®Google Scholar
• Riederer P, Lachenmayer L. Selegiline’s neuroprotective capacity revisited. J. Neural Transm. 110(11), 1273–1278 (2003).
   PubMed Web of Science ®Google Scholar
• Magyar K, Pálfi M, Tábi T, Kalász H, Szende B, Szöko E. Pharmacological aspects of (-)-deprenyl. Curr. Med. Chem. 11(15), 2017–2031 (2004).
   PubMed Web of Science ®Google Scholar
• Ebadi M, Brown-Borg H, Ren J et al. Therapeutic efficacy of selegiline in neurodegenerative disorders and neurological diseases. Curr. Drug Targets 7(11), 1513–1529 (2006).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Edmondson D, Tipton KF. The therapeutic potential of monoamine oxidase inhibitors. Nat. Rev. Neurosci. 7(4), 295–309 (2006).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W. Monoamine oxidase inhibitors as neuroprotective agents in age-dependent neurodegenerative disorders. Curr. Pharm. Des. 16(25), 2799–2817 (2010).
   PubMed Web of Science ®Google Scholar
• Damier P, Kastner A, Agid Y, Hirsch EC. Does monoamine oxidase type B play a role in dopaminergic nerve cell death in Parkinson’s disease? Neurology 46(5), 1262–1269 (1996).
   PubMed Web of Science ®Google Scholar
• Kumar MJ, Andersen JK. Perspectives on MAO-B in aging and neurological disease: where do we go from here? Mol. Neurobiol. 30(1), 77–89 (2004).
   PubMed Web of Science ®Google Scholar
• Mallajosyula JK, Kaur D, Chinta SJ et al. MAO-B elevation in mouse brain astrocytes results in Parkinson’s pathology. PLoS ONE 3(2), e1616 (2008).
   PubMed Web of Science ®Google Scholar
• Yi H, Akao Y, Maruyama W, Chen K, Shih J, Naoi M. Type A monoamine oxidase is the target of an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, leading to apoptosis in SH-SY5Y cells. J. Neurochem. 96(2), 541–549 (2006).
   PubMed Web of Science ®Google Scholar
• De Zutter GS, Davis RJ. Pro-apoptotic gene expression mediated by the p38 mitogen-activated protein kinase signal transduction pathway. Proc. Natl Acad. Sci. USA 98(11), 6168–6173 (2001).
   PubMed Web of Science ®Google Scholar
• Ou XM, Chen K, Shih JC. Monoamine oxidase A and repressor R1 are involved in apoptotic signaling pathway. Proc. Natl Acad. Sci. USA 103(29), 10923–10928 (2006).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JC, Ufer C, De Girolamo LA, Kuhn H, Billett EE. Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells. J. Neurochem. 103(6), 2189–2199 (2007).
   PubMed Web of Science ®Google Scholar
• Fitzgerald JC, Ufer C, Billett EE. A link between monoamine oxidase-A and apoptosis in serum deprived human SH-SY5Y neuroblastoma cells. J. Neural Transm. 114(6), 807–810 (2007).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Nitta A, Shamoto-Nagai M et al. N-Propargyl-1®-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem. Int. 44(6), 393–400 (2004).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Inaba-Hasegawa K, Akao Y. Type A monoamine oxidase regulates life and death of neurons in neurodegeneration and neuroprotection. Int. Rev. Neurobiol. 100, 85–106 (2011).
   PubMed Web of Science ®Google Scholar
• Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M. Type A monoamine oxidase is associated with induction of neuroprotective Bcl-2 by rasagiline, an inhibitor of type B monoamine oxidase. J. Neural Transm. 119(4), 405–414 (2012).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Naoi M. Induction of glial cell-line-derived and brain-derived neurotrophic factors by rasagiline and (-)deprenyl: a way to a disease-modifying therapy? J. Neural Transm. 120, 83–89 (2013).
   PubMed Web of Science ®Google Scholar
• Heikkila RE, Manzino L, Cabbat FS, Duvoisin RC. Studies on the oxidation of the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine by monoamine oxidase B. J. Neurochem. 45(4), 1049–1054 (1985).
   PubMed Web of Science ®Google Scholar
• Heikkila RE, Duvoisin RC, Finberg JP, Youdim MB. Prevention of MPTP-induced neurotoxicity by AGN-1133 and AGN-1135, selective inhibitors of monoamine oxidase-B. Eur. J. Pharmacol. 116(3), 313–317 (1985).
   PubMed Web of Science ®Google Scholar
• Kupsch A, Sautter J, Götz ME et al. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline. J. Neural Transm. 108(8–9), 985–1009 (2001).
   PubMed Web of Science ®Google Scholar
• Sharma SK, Carlson EC, Ebadi M. Neuroprotective actions of selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J. Neurocytol. 32(4), 329–343 (2003).
   PubMedGoogle Scholar
• Blandini F, Armentero MT, Fancellu R, Blaugrund E, Nappi G. Neuroprotective effect of rasagiline in a rodent model of Parkinson’s disease. Exp. Neurol. 187(2), 455–459 (2004).
   PubMed Web of Science ®Google Scholar
• Zhang X, Zuo DM, Davis BA, Boulton AA, Yu PH. Immunohistochemical evidence of neuroprotection by R(-)-deprenyl and N-(2-hexyl)-N-methylpropargylamine on DSP-4-induced degeneration of rat brain noradrenergic axons and terminals. J. Neurosci. Res. 43(4), 482–489 (1996).
   PubMed Web of Science ®Google Scholar
• Fowler CJ, Tipton KF. Deamination of 5-hydroxytryptamine by both forms of monoamine oxidase in the rat brain. J. Neurochem. 38(3), 733–736 (1982).
   PubMed Web of Science ®Google Scholar
• Ricci A, Mancini M, Strocchi P, Bongrani S, Bronzetti E. Deficits in cholinergic neurotransmission markers induced by ethylcholine mustard aziridinium (AF64A) in the rat hippocampus: sensitivity to treatment with the monoamine oxidase-B inhibitor L-deprenyl. Drugs Exp. Clin. Res. 18(5), 163–171 (1992).
   PubMedGoogle Scholar
• Salo PT, Tatton WG. Deprenyl reduces the death of motoneurons caused by axotomy. J. Neurosci. Res. 31(2), 394–400 (1992).
   PubMed Web of Science ®Google Scholar
• Speiser Z, Katzir O, Rehavi M, Zabarski T, Cohen S. Sparing by rasagiline (TVP-1012) of cholinergic functions and behavior in the postnatal anoxia rat. Pharmacol. Biochem. Behav. 60(2), 387–393 (1998).
   PubMed Web of Science ®Google Scholar
• Speiser Z, Mayk A, Litinetsky L et al. Rasagiline is neuroprotective in an experimental model of brain ischemia in the rat. J. Neural Transm. 114(5), 595–605 (2007).
   PubMed Web of Science ®Google Scholar
• Stefanova N, Poewe W, Wenning GK. Rasagiline is neuroprotective in a transgenic model of multiple system atrophy. Exp. Neurol. 210(2), 421–427 (2008).
   PubMed Web of Science ®Google Scholar
• Eliash S, Dror V, Cohen S, Rehavi M. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res. 1256, 138–148 (2009).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Abe T, Tohgi H, Dostert P, Naoi M. A dopaminergic neurotoxin, (R)-N-methylsalsolinol, increases in Parkinsonian cerebrospinal fluid. Ann. Neurol. 40(1), 119–122 (1996).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Nakao N, Ibi T, Sahashi K, Benedetti MS. (R)salsolinol N-methyltransferase activity increases in Parkinsonian lymphocytes. Ann. Neurol. 43(2), 212–216 (1998).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Dostert P et al. Dopamine-derived endogenous 1(R),2(N)-dimethyl-6,7-dihydroxy-1,2,3,4-tetrahydroisoquinoline, N-methyl-(R)-salsolinol, induced parkinsonism in rat: biochemical, pathological and behavioral studies. Brain Res. 709(2), 285–295 (1996).
   PubMed Web of Science ®Google Scholar
• Akao Y, Nakagawa Y, Maruyama W, Takahashi T, Naoi M. Apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, is mediated by activation of caspase 3. Neurosci. Lett. 267(3), 153–156 (1999).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Boulton AA, Davis BA, Dostert P, Naoi M. Enantio-specific induction of apoptosis by an endogenous neurotoxin, N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N-methylpropargylamine. J. Neural Transm. 108(1), 11–24 (2001).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Naoi M, Kasamatsu T et al. An endogenous dopaminergic neurotoxin, N-methyl-(R)-salsolinol, induces DNA damage in human dopaminergic neuroblastoma SH-SY5Y cells. J. Neurochem. 69(1), 322–329 (1997).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Akao Y, Youdim MB, Davis BA, Naoi M. Transfection-enforced Bcl-2 overexpression and an anti-Parkinson drug, rasagiline, prevent nuclear accumulation of glyceraldehyde-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J. Neurochem. 78(4), 727–735 (2001).
   PubMed Web of Science ®Google Scholar
• Akao Y, Maruyama W, Shimizu S et al. Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J. Neurochem. 82(4), 913–923 (2002).
   PubMed Web of Science ®Google Scholar
• Green DR, Kroemer G. The pathophysiology of mitochondrial cell death. Science 305(5684), 626–629 (2004).
   PubMed Web of Science ®Google Scholar
• Kroemer G, Galluzzi L, Brenner C. Mitochondrial membrane permeabilization in cell death. Physiol. Rev. 87(1), 99–163 (2007).
   PubMed Web of Science ®Google Scholar
• Kinnally KW, Antonsson B. A tale of two mitochondrial channels, MAC and PTP, in apoptosis. Apoptosis 12(5), 857–868 (2007).
   PubMed Web of Science ®Google Scholar
• Galluzzi L, Blomgren K, Kroemer G. Mitochondrial membrane permeabilization in neuronal injury. Nat. Rev. Neurosci. 10(7), 481–494 (2009).
   PubMed Web of Science ®Google Scholar
• Beutner G, Rück A, Riede B, Brdiczka D. Complexes between porin, hexokinase, mitochondrial creatine kinase and adenylate translocator display properties of the permeability transition pore. Implication for regulation of permeability transition by the kinases. Biochim. Biophys. Acta 1368(1), 7–18 (1998).
   PubMed Web of Science ®Google Scholar
• Rasola A, Bernardi P. The mitochondrial permeability transition pore and its involvement in cell death and in disease pathogenesis. Apoptosis 12(5), 815–833 (2007).
   PubMed Web of Science ®Google Scholar
• Kinnally KW, Peixoto PM, Ryu SY, Dejean LM. Is mPTP the gatekeeper for necrosis, apoptosis, or both? Biochim. Biophys. Acta 1813(4), 616–622 (2011).
   PubMed Web of Science ®Google Scholar
• Sileikyte J, Petronilli V, Zulian A et al. Regulation of the inner membrane mitochondrial permeability transition by the outer membrane translocator protein (peripheral benzodiazepine receptor). J. Biol. Chem. 286(2), 1046–1053 (2011).
   PubMed Web of Science ®Google Scholar
• Tsujimoto Y, Shimizu S. VDAC regulation by the Bcl-2 family of proteins. Cell Death Differ. 7(12), 1174–1181 (2000).
   PubMed Web of Science ®Google Scholar
• Wadia JS, Chalmers-Redman RM, Ju WJ et al. Mitochondrial membrane potential and nuclear changes in apoptosis caused by serum and nerve growth factor withdrawal: time course and modification by (-)-deprenyl. J. Neurosci. 18(3), 932–947 (1998).
   PubMed Web of Science ®Google Scholar
• Lee CS, Lee CS, Ko HH, Song JH, Han ES. Effect of R-(-)-deprenyl and harmaline on dopamine- and peroxynitrite-induced membrane permeability transition in brain mitochondria. Neurochem. Res. 27(3), 215–224 (2002).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Naoi M. Neuroprotection by (-)-deprenyl and related compounds. Mech. Ageing Dev. 111(2–3), 189–200 (1999).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Yamamoto T, Kitani K, Carrillo MC, Youdim M, Naoi M. Mechanism underlying anti-apoptotic activity of a (-)deprenyl-related propargylamine, rasagiline. Mech. Ageing Dev. 116(2–3), 181–191 (2000).
   PubMed Web of Science ®Google Scholar
• Maruyama W, Akao Y, Carrillo MC, Kitani K, Youdium MB, Naoi M. Neuroprotection by propargylamines in Parkinson’s disease: suppression of apoptosis and induction of prosurvival genes. Neurotoxicol. Teratol. 24(5), 675–682 (2002).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Yi H. Rasagiline prevents apoptosis induced by PK11195, a ligand of outer membrane translocator protein (18 kDA), in SH-SY5Y cells through suppression of cytochrome c release from mitochondria. J. Neural Transm. (2013) (In Press).
   Google Scholar
• Galluzzi L, Morselli E, Kepp O, Kroemer G. Targeting post-mitochondrial effectors of apoptosis for neuroprotection. Biochim. Biophys. Acta 1787(5), 402–413 (2009).
   PubMed Web of Science ®Google Scholar
• Sayeed I, Parvez S, Wali B, Siemen D, Stein DG. Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism for better neuroprotective effects of allopregnanolone over progesterone. Brain Res. 1263, 165–173 (2009).
   PubMed Web of Science ®Google Scholar
• Martel C, Huynh le H, Garnier A, Ventura-Clapier R, Brenner C. Inhibition of the mitochondrial permeability transition for cytoprotection: direct versus indirect mechanisms. Biochem. Res. Int. 2012, 213403 (2012).
   PubMedGoogle Scholar
• Soane L, Fiskum G. Inhibition of mitochondrial neural cell death pathways by protein transduction of Bcl-2 family proteins. J. Bioenerg. Biomembr. 37(3), 179–190 (2005).
   PubMed Web of Science ®Google Scholar
• Vila M, Jackson-Lewis V, Vukosavic S et al. Bax ablation prevents dopaminergic neurodegeneration in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Proc. Natl Acad. Sci. USA 98(5), 2837–2842 (2001).
   PubMed Web of Science ®Google Scholar
• Youdim MB, Bakhle YS. Monoamine oxidase: isoforms and inhibitors in Parkinson’s disease and depressive illness. Br. J. Pharmacol. 147(Suppl. 1), S287–S296 (2006).
   PubMed Web of Science ®Google Scholar
• Wu RM, Chiueh CC, Pert A, Murphy DL. Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur. J. Pharmacol. 243(3), 241–247 (1993).
   PubMed Web of Science ®Google Scholar
• Thomas CE, Huber EW, Ohlweiler DF. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors deprenyl and MDL 72,974A: implications for protection of biological substrates. Free Radic. Biol. Med. 22(4), 733–737 (1997).
   PubMed Web of Science ®Google Scholar
• Kitani K, Minami C, Isobe K et al. Why (-)deprenyl prolongs survivals of experimental animals: increase of anti-oxidant enzymes in brain and other body tissues as well as mobilization of various humoral factors may lead to systemic anti-aging effects. Mech. Ageing Dev. 123(8), 1087–1100 (2002).
   PubMed Web of Science ®Google Scholar
• Subramanian MV, James TJ. Age-related protective effect of deprenyl on changes in the levels of diagnostic marker enzymes and antioxidant defense enzymes activities in cerebellar tissue in Wistar rats. Cell Stress Chaperones 15(5), 743–751 (2010).
   PubMed Web of Science ®Google Scholar
• Andoh T, Chock PB, Murphy DL, Chiueh CC. Role of the redox protein thioredoxin in cytoprotective mechanism evoked by (-)-deprenyl. Mol. Pharmacol. 68(5), 1408–1414 (2005).
   PubMed Web of Science ®Google Scholar
• Carlile GW, Chalmers-Redman RM, Tatton NA, Pong A, Borden KE, Tatton WG. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehyde-3-phosphate dehydrogenase to a dimer. Mol. Pharmacol. 57(1), 2–12 (2000).
   PubMed Web of Science ®Google Scholar
• Ou XM, Stockmeier CA, Meltzer HY et al. A novel role for glyceraldehyde-3-phosphate dehydrogenase and monoamine oxidase B cascade in ethanol-induced cellular damage. Biol. Psychiatry 67(9), 855–863 (2010).
   PubMed Web of Science ®Google Scholar
• Hara MR, Thomas B, Cascio MB et al. Neuroprotection by pharmacologic blockade of the GAPDH death cascade. Proc. Natl Acad. Sci. USA 103(10), 3887–3889 (2006).
   PubMed Web of Science ®Google Scholar
• Ou XM, Lu D, Johnson C et al. Glyceraldehyde-3-phosphate dehydrogenase-monoamine oxidase B-mediated cell death-induced by ethanol is prevented by rasagiline and 1-R-aminoindan. Neurotox. Res. 16(2), 148–159 (2009).
   PubMed Web of Science ®Google Scholar
• Shacka JJ, Roth KA. Regulation of neuronal cell death and neurodegeneration by members of the Bcl-2 family: therapeutic implications. Curr. Drug Targets. CNS Neurol. Disord. 4(1), 25–39 (2005).
   PubMedGoogle Scholar
• Schwartz PS, Hockenbery DM. Bcl-2-related survival proteins. Cell Death Differ. 13(8), 1250–1255 (2006).
   PubMed Web of Science ®Google Scholar
• Shimizu S, Konishi A, Kodama T, Tsujimoto Y. BH4 domain of antiapoptotic Bcl-2 family members closes voltage-dependent anion channel and inhibits apoptotic mitochondrial changes and cell death. Proc. Natl Acad. Sci. USA 97(7), 3100–3105 (2000).
   PubMed Web of Science ®Google Scholar
• Malik JM, Shevtsova Z, Bähr M, Kügler S. Long-term in vivo inhibition of CNS neurodegeneration by Bcl-XL gene transfer. Mol. Ther. 11(3), 373–381 (2005).
   PubMed Web of Science ®Google Scholar
• Offen D, Beart PM, Cheung NS et al. Transgenic mice expressing human Bcl-2 in their neurons are resistant to 6-hydroxydopamine and 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine neurotoxicity. Proc. Natl Acad. Sci. USA 95(10), 5789–5794 (1998).
   PubMed Web of Science ®Google Scholar
• Natsume A, Mata M, Goss J et al. Bcl-2 and GDNF delivered by HSV-mediated gene transfer act additively to protect dopaminergic neurons from 6-OHDA-induced degeneration. Exp. Neurol. 169(2), 231–238 (2001).
   PubMed Web of Science ®Google Scholar
• Cao YJ, Shibata T, Rainov NG. Liposome-mediated transfer of the Bcl-2 gene results in neuroprotection after in vivo transient focal cerebral ischemia in an animal model. Gene Ther. 9(6), 415–419 (2002).
   PubMed Web of Science ®Google Scholar
• Yang J, Liu X, Bhalla K et al. Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275(5303), 1129–1132 (1997).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Akao Y, Yi H, Yamaoka Y. Involvement of type A monoamine oxidase in neurodegeneration: regulation of mitochondrial signaling leading to cell death or neuroprotection. J. Neural Transm. Suppl. 71, 67–77 (2006).
   Google Scholar
• Naoi M, Maruyama W, Inaba-Hasegawa K. Type A and B monoamine oxidase in age-related neurodegenerative disorders: their distinct roles in neuronal death and survival. Curr. Top. Med. Chem. 12(20), 2177–2188 (2012).
   PubMed Web of Science ®Google Scholar
• Chiou SH, Ku HH, Tsai TH et al. Moclobemide upregulated Bcl-2 expression and induced neural stem cell differentiation into serotoninergic neuron via extracellular-regulated kinase pathway. Br. J. Pharmacol. 148(5), 587–598 (2006).
   PubMed Web of Science ®Google Scholar
• Yi H, Maruyama W, Akao Y et al. N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2. J. Neural Transm. 113(1), 21–32 (2006).
   PubMed Web of Science ®Google Scholar
• Grimsby J, Toth M, Chen K et al. Increased stress response and β-phenylethylamine in MAOB-deficient mice. Nat. Genet. 17(2), 206–210 (1997).
   PubMed Web of Science ®Google Scholar
• Ekblom J, Oreland L, Chen K, Shih JC. Is there a ‘non-MAO’ macromolecular target for L-deprenyl?: studies on MAOB mutant mice. Life Sci. 63(12), PL181–PL186 (1998).
   PubMed Web of Science ®Google Scholar
• Pugazhenthi S, Nesterova A, Sable C et al. Akt/protein kinase B up-regulates Bcl-2 expression through cAMP-response element-binding protein. J. Biol. Chem. 275(15), 10761–10766 (2000).
   PubMed Web of Science ®Google Scholar
• Naoi M, Maruyama W, Yi H, Akao Y, Yamaoka Y, Shamoto-Nagai M. Neuroprotection by propargylamines in Parkinson’s disease: intracellular mechanism underlying the anti-apoptotic function and search for clinical markers. J. Neural Transm. Suppl. 72, 121–131 (2007).
   Google Scholar
• Cammarota M, Paratcha G, Bevilaqua LR et al. Cyclic AMP-responsive element binding protein in brain mitochondria. J. Neurochem. 72(6), 2272–2277 (1999).
   PubMed Web of Science ®Google Scholar
• Lee J, Kim CH, Simon DK et al. Mitochondrial cyclic AMP response element-binding protein (CREB) mediates mitochondrial gene expression and neuronal survival. J. Biol. Chem. 280(49), 40398–40401 (2005).
   PubMed Web of Science ®Google Scholar
• Kulich SM, Horbinski C, Patel M, Chu CT. 6-Hydroxydopamine induces mitochondrial ERK activation. Free Radic. Biol. Med. 43(3), 372–383 (2007).
   PubMed Web of Science ®Google Scholar
• Shih JC, Chen K. Regulation of MAO-A and MAO-B gene expression. Curr. Med. Chem. 11(15), 1995–2005 (2004).
   PubMed Web of Science ®Google Scholar
• Shih JC, Wu JB, Chen K. Transcriptional regulation and multiple functions of MAO genes. J. Neural Transm. 118(7), 979–986 (2011).
   PubMed Web of Science ®Google Scholar
• Ou XM, Chen K, Shih JC. Glucocorticoid and androgen activation of monoamine oxidase A is regulated differently by R1 and Sp1. J. Biol. Chem. 281(30), 21512–21525 (2006).
   PubMed Web of Science ®Google Scholar
• Duncan J, Johnson S, Ou XM. Monoamine oxidases in major depressive disorder and alcoholism. Drug Discov. Ther. 6(3), 112–122 (2012).
   PubMedGoogle Scholar
• Cao X, Li XM, Mousseau DD. Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signalling pathways. Life Sci. 85(5–6), 262–268 (2009).
   PubMed Web of Science ®Google Scholar
• Wu JB, Shih JC. Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation. Mol. Pharmacol. 80(4), 714–723 (2011).
   PubMed Web of Science ®Google Scholar
• Inaba-Hasegawa K, Akao Y, Maruyama W, Naoi M. Rasagiline and selegiline, inhibitors of type B monoamine oxidase, induce type A monoamine oxidase in human SH-SY5Y cells. J. Neural Transm. 120(3), 435–444 (2013).
   PubMed Web of Science ®Google Scholar
• Hubálek F, Binda C, Li M et al. Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues. J. Med. Chem. 47(7), 1760–1766 (2004).
   PubMed Web of Science ®Google Scholar
• Binda C, Hubálek F, Li M et al. Binding of rasagiline-related inhibitors to human monoamine oxidases: a kinetic and crystallographic analysis. J. Med. Chem. 48(26), 8148–8154 (2005).
   PubMed Web of Science ®Google Scholar
• Raddatz R, Parini A, Lanier SM. Imidazoline/guanidinium binding domains on monoamine oxidases. Relationship to subtypes of imidazoline-binding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase B. J. Biol. Chem. 270(46), 27961–27968 (1995).
   PubMed Web of Science ®Google Scholar
• Anderson NJ, Seif I, Nutt DJ, Hudson AL, Robinson ES. Autoradiographical distribution of imidazoline binding sites in monoamine oxidase A deficient mice. J. Neurochem. 96(6), 1551–1559 (2006).
   PubMed Web of Science ®Google Scholar
• Barac YD, Bar-Am O, Liani E et al. I1 imidazoline receptor: novel potential cytoprotective target of TVP1022, the S-enantiomer of rasagiline. PLoS ONE 7(11), e47890 (2012).
   PubMedGoogle Scholar
• Pizzinat N, Marchal-Victorion S, Maurel A, Ordener C, Bompart G, Parini A. Substrate-dependent regulation of MAO-A in rat mesangial cells: involvement of dopamine D2-like receptors. Am. J. Physiol. Renal Physiol. 284(1), F167–F174 (2003).
   PubMed Web of Science ®Google Scholar
• Riedel O, Heuser I, Klotsche J, Dodel R, Wittchen HU; GEPAD Study Group. Occurrence risk and structure of depression in Parkinson disease with and without dementia: results from the GEPAD Study. J. Geriatr. Psychiatry Neurol. 23(1), 27–34 (2010).
   PubMed Web of Science ®Google Scholar
• Riederer P, Laux G. MAO-inhibitors in Parkinson’s Disease. Exp. Neurobiol. 20(1), 1–17 (2011).
   PubMedGoogle Scholar
• Reichardt LF. Neurotrophin-regulated signalling pathways. Philos. Trans. R. Soc. Lond. B Biol. Sci. 361(1473), 1545–1564 (2006).
   PubMed Web of Science ®Google Scholar
• Pascual A, Hidalgo-Figueroa M, Piruat JI, Pintado CO, Gómez-Díaz R, López-Barneo J. Absolute requirement of GDNF for adult catecholaminergic neuron survival. Nat. Neurosci. 11(7), 755–761 (2008).
   PubMed Web of Science ®Google Scholar
• Rangasamy SB, Soderstrom K, Bakay RA, Kordower JH. Neurotrophic factor therapy for Parkinson’s disease. Prog. Brain Res. 184, 237–264 (2010).
   PubMed Web of Science ®Google Scholar
• Ichim G, Tauszig-Delamasure S, Mehlen P. Neurotrophins and cell death. Exp. Cell Res. 318(11), 1221–1228 (2012).
   PubMed Web of Science ®Google Scholar
• Airaksinen MS, Saarma M. The GDNF family: signalling, biological functions and therapeutic value. Nat. Rev. Neurosci. 3(5), 383–394 (2002).
   PubMed Web of Science ®Google Scholar
• Paratcha G, Ledda F. GDNF and GFRα: a versatile molecular complex for developing neurons. Trends Neurosci. 31(8), 384–391 (2008).
   PubMed Web of Science ®Google Scholar
• Chauhan NB, Siegel GJ, Lee JM. Depletion of glial cell line-derived neurotrophic factor in substantia nigra neurons of Parkinson’s disease brain. J. Chem. Neuroanat. 21(4), 277–288 (2001).
   PubMed Web of Science ®Google Scholar
• Choi-Lundberg DL, Lin Q, Chang YN et al. Dopaminergic neurons protected from degeneration by GDNF gene therapy. Science 275(5301), 838–841 (1997).
   PubMed Web of Science ®Google Scholar
• Oo TF, Kholodilov N, Burke RE. Regulation of natural cell death in dopaminergic neurons of the substantia nigra by striatal glial cell line-derived neurotrophic factor in vivo. J. Neurosci. 23(12), 5141–5148 (2003).
   PubMed Web of Science ®Google Scholar
• Sun M, Kong L, Wang X, Lu XG, Gao Q, Geller AI. Comparison of the capability of GDNF, BDNF, or both, to protect nigrostriatal neurons in a rat model of Parkinson’s disease. Brain Res. 1052(2), 119–129 (2005).
   PubMed Web of Science ®Google Scholar
• Pascual A, Hidalgo-Figueroa M, Gómez-Díaz R, López-Barneo J. GDNF and protection of adult central catecholaminergic neurons. J. Mol. Endocrinol. 46(3), R83–R92 (2011).
   PubMed Web of Science ®Google Scholar
• Burke RE, Antonelli M, Sulzer D. Glial cell line-derived neurotrophic growth factor inhibits apoptotic death of postnatal substantia nigra dopamine neurons in primary culture. J. Neurochem. 71(2), 517–525 (1998).
   PubMed Web of Science ®Google Scholar
• Tomac A, Widenfalk J, Lin LF et al. Retrograde axonal transport of glial cell line-derived neurotrophic factor in the adult nigrostriatal system suggests a trophic role in the adult. Proc. Natl Acad. Sci. USA 92(18), 8274–8278 (1995).
   PubMed Web of Science ®Google Scholar
• Biju K, Zhou Q, Li G et al. Macrophage-mediated GDNF delivery protects against dopaminergic neurodegeneration: a therapeutic strategy for Parkinson’s disease. Mol. Ther. 18(8), 1536–1544 (2010).
   PubMed Web of Science ®Google Scholar
• Fletcher AM, Kowalczyk TH, Padegimas L, Cooper MJ, Yurek DM. Transgene expression in the striatum following intracerebral injections of DNA nanoparticles encoding for human glial cell line-derived neurotrophic factor. Neuroscience 194, 220–226 (2011).
   PubMed Web of Science ®Google Scholar
• Ciesielska A, Mittermeyer G, Hadaczek P, Kells AP, Forsayeth J, Bankiewicz KS. Anterograde axonal transport of AAV2-GDNF in rat basal ganglia. Mol. Ther. 19(5), 922–927 (2011).
   PubMed Web of Science ®Google Scholar
• Kirik D, Georgievska B, Björklund A. Localized striatal delivery of GDNF as a treatment for Parkinson disease. Nat. Neurosci. 7(2), 105–110 (2004).
   PubMed Web of Science ®Google Scholar
• Gill SS, Patel NK, Hotton GR et al. Direct brain infusion of glial cell line-derived neurotrophic factor in Parkinson disease. Nat. Med. 9(5), 589–595 (2003).
   PubMed Web of Science ®Google Scholar
• Hong M, Mukhida K, Mendez I. GDNF therapy for Parkinson’s disease. Expert Rev. Neurother. 8(7), 1125–1139 (2008).
   PubMedGoogle Scholar
• Aron L, Klein R. Repairing the Parkinsonian brain with neurotrophic factors. Trends Neurosci. 34(2), 88–100 (2011).
   PubMed Web of Science ®Google Scholar
• Slevin JT, Gash DM, Smith CD et al. Unilateral intraputamenal glial cell line-derived neurotrophic factor in patients with Parkinson disease: response to 1 year of treatment and 1 year of withdrawal. J. Neurosurg. 106(4), 614–620 (2007).
   PubMed Web of Science ®Google Scholar
• Lang AE, Gill S, Patel NK et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann. Neurol. 59(3), 459–466 (2006).
   PubMed Web of Science ®Google Scholar
• Saavedra A, Baltazar G, Duarte EP. Driving GDNF expression: the green and the red traffic lights. Prog. Neurobiol. 86(3), 186–215 (2008).
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Weinreb O, Amit T, Youdim MB. Regulation of Bcl-2 family proteins, neurotrophic factors, and APP processing in the neurorescue activity of propargylamine. FASEB J. 19(13), 1899–1901 (2005).
   PubMed Web of Science ®Google Scholar
• Weinreb O, Amit T, Bar-Am O, Sagi Y, Mandel S, Youdim MB. Involvement of multiple survival signal transduction pathways in the neuroprotective, neurorescue and APP processing activity of rasagiline and its propargyl moiety. J. Neural Transm. Suppl. 70, 457–465 (2006).
   Google Scholar
• Weinreb O, Amit T, Bar-Am O, Youdim MB. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy. Ann. NY Acad. Sci. 1122, 155–168 (2007).
   PubMed Web of Science ®Google Scholar
• Mizuta I, Ohta M, Ohta K et al. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 279(3), 751–755 (2000).
   PubMed Web of Science ®Google Scholar
• Tang YP, Ma YL, Chao CC, Chen KY, Lee EH. Enhanced glial cell line-derived neurotrophic factor mRNA expression upon (-)-deprenyl and melatonin treatments. J. Neurosci. Res. 53(5), 593–604 (1998).
   PubMed Web of Science ®Google Scholar
• Mandel SA, Sagi Y, Amit T. Rasagiline promotes regeneration of substantia nigra dopaminergic neurons in post-MPTP-induced Parkinsonism via activation of tyrosine kinase receptor signaling pathway. Neurochem. Res. 32(10), 1694–1699 (2007).
   PubMed Web of Science ®Google Scholar
• Sagi Y, Mandel S, Amit T, Youdim MB. Activation of tyrosine kinase receptor signaling pathway by rasagiline facilitates neurorescue and restoration of nigrostriatal dopamine neurons in post-MPTP-induced parkinsonism. Neurobiol. Dis. 25(1), 35–44 (2007).
   PubMed Web of Science ®Google Scholar
• Parain K, Murer MG, Yan Q et al. Reduced expression of brain-derived neurotrophic factor protein in Parkinson’s disease substantia nigra. Neuroreport 10(3), 557–561 (1999).
   PubMed Web of Science ®Google Scholar
• Levivier M, Przedborski S, Bencsics C, Kang UJ. Intrastriatal implantation of fibroblasts genetically engineered to produce brain-derived neurotrophic factor prevents degeneration of dopaminergic neurons in a rat model of Parkinson’s disease. J. Neurosci. 15(12), 7810–7820 (1995).
   PubMed Web of Science ®Google Scholar
• Gyárfás T, Knuuttila J, Lindholm P, Rantamäki T, Castrén E. Regulation of brain-derived neurotrophic factor (BDNF) and cerebral dopamine neurotrophic factor (CDNF) by anti-Parkinsonian drug therapy in vivo. Cell. Mol. Neurobiol. 30(3), 361–368 (2010).
   PubMed Web of Science ®Google Scholar
• Kontkanen O, Castrén E. Trophic effects of selegiline on cultured dopaminergic neurons. Brain Res. 829(1–2), 190–192 (1999).
   PubMed Web of Science ®Google Scholar
• Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 64(6), 527–532 (2008).
   PubMed Web of Science ®Google Scholar
• Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature 455(7215), 894–902 (2008).
   PubMed Web of Science ®Google Scholar
• Balu DT, Hoshaw BA, Malberg JE, Rosenzweig-Lipson S, Schechter LE, Lucki I. Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments. Brain Res. 1211, 37–43 (2008).
   PubMed Web of Science ®Google Scholar
• Drzyzga LR, Marcinowska A, Obuchowicz E. Antiapoptotic and neurotrophic effects of antidepressants: a review of clinical and experimental studies. Brain Res. Bull. 79(5), 248–257 (2009).
   PubMed Web of Science ®Google Scholar
• Chang YC, Rapoport SI, Rao JS. Chronic administration of mood stabilizers upregulates BDNF and bcl-2 expression levels in rat frontal cortex. Neurochem. Res. 34(3), 536–541 (2009).
   PubMed Web of Science ®Google Scholar
• Eliash S, Dror V, Cohen S, Rehavi M. Neuroprotection by rasagiline in thiamine deficient rats. Brain Res. 1256, 138–148 (2009).
   PubMed Web of Science ®Google Scholar
• Tazik S, Johnson S, Lu D et al. Comparative neuroprotective effects of rasagiline and aminoindan with selegiline on dexamethasone-induced brain cell apoptosis. Neurotox. Res. 15(3), 284–290 (2009).
   PubMed Web of Science ®Google Scholar
• Shirayama Y, Chen AC, Nakagawa S, Russell DS, Duman RS. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J. Neurosci. 22(8), 3251–3261 (2002).
   PubMed Web of Science ®Google Scholar
• Westlund KN, Denney RM, Rose RM, Abell CW. Localization of distinct monoamine oxidase A and monoamine oxidase B cell populations in human brainstem. Neuroscience 25(2), 439–456 (1988).
   PubMed Web of Science ®Google Scholar
• Riederer P, Konradi C, Hebenstreit G, Youdim MB. Neurochemical perspectives to the function of monoamine oxidase. Acta Neurol. Scand. Suppl. 126, 41–45 (1989).
   PubMedGoogle Scholar
• Shih JC, Chen K, Ridd MJ. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 22, 197–217 (1999).
   PubMed Web of Science ®Google Scholar
• Wang J, Edmondson DE. Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis. Biochemistry 50(13), 2499–2505 (2011).
   PubMed Web of Science ®Google Scholar
• Bresjanac M, Antauer G. Reactive astrocytes of the quinolinic acid-lesioned rat striatum express GFRα1 as well as GDNF in vivo. Exp. Neurol. 164(1), 53–59 (2000).
   PubMed Web of Science ®Google Scholar
• Li X, Oghi KA, Zhang J et al. Eya protein phosphatase activity regulates Six1-Dach-Eya transcriptional effects in mammalian organogenesis. Nature 426(6964), 247–254 (2003).
   PubMed Web of Science ®Google Scholar
• Kobayashi H, Kawakami K, Asashima M, Nishinakamura R. Six1 and Six4 are essential for Gdnf expression in the metanephric mesenchyme and ureteric bud formation, while Six1 deficiency alone causes mesonephric-tubule defects. Mech. Dev. 124(4), 290–303 (2007).
   PubMed Web of Science ®Google Scholar
• Wellik DM, Hawkes PJ, Capecchi MR. Hox11 paralogous genes are essential for metanephric kidney induction. Genes Dev. 16(11), 1423–1432 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease. The TEMPO study. Arch. Neurol. 59, 1937–1943 (2002).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch. Neurol. 61, 561–566 (2004).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A randomized placebo-controlled trial of rasagiline in Levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch. Neurol. 62, 241–248 (2005).
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R et al.; ADAGIO Study Investigators. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N. Engl. J. Med. 361(13), 1268–1278 (2009).
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson’s disease. N. Engl. J. Med. 321, 1364–1371 (1989).
   PubMed Web of Science ®Google Scholar
• Ives NJ, Stowe RL, Marro J et al. Monoamine oxidase type B inhibitors in early Parkinson’s disease: meta-analysis of 17 randomised trials involving 3525 patients. BMJ 329(7466), 593 (2004).
   PubMed Web of Science ®Google Scholar
• Hung AY, Schwarzschild MA. Clinical trials for neuroprotection in Parkinson’s disease: overcoming angst and futility? Curr. Opin. Neurol. 20(4), 477–483 (2007).
   PubMed Web of Science ®Google Scholar
• Melega WP, Cho AK, Schmitz D, Kuczenski R, Segal DS. l-methamphetamine pharmacokinetics and pharmacodynamics for assessment of in vivo deprenyl-derived l-methamphetamine. J. Pharmacol. Exp. Ther. 288(2), 752–758 (1999).
   PubMed Web of Science ®Google Scholar
• Stephans S, Yamamoto B. Methamphetamines pretreatment and the vulnerability of the striatum to methamphetamine neurotoxicity. Neuroscience 72(3), 593–600 (1996).
   PubMed Web of Science ®Google Scholar
• Bar Am O, Amit T, Youdim MB. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 355(3), 169–172 (2004).
   PubMed Web of Science ®Google Scholar
• Bar-Am O, Amit T, Youdim MB. Aminoindan and hydroxyaminoindan, metabolites of rasagiline and ladostigil, respectively, exert neuroprotective properties in vitro. J. Neurochem. 103(2), 500–508 (2007).
   PubMed Web of Science ®Google Scholar
• Shoulson I. An interim report of the effect of selegiline (l-deprenyl) on the progression of disability in early Parkinson’s disease. The Parkinson Study Group. Eur. Neurol. 32(Suppl. 1), 46–53 (1992).
   PubMed Web of Science ®Google Scholar
• Vanacore N. What is the clinical significance of the findings from the delayed-start trial of rasagiline in Parkinson’s disease? Neuroepidemiology 35(3), 213 (2010).
   PubMed Web of Science ®Google Scholar
• Korczyn AD, Vakhapova V. Delayed start, rapid solution? Neuroepidemiology 35(3), 214 (2010).
   PubMed Web of Science ®Google Scholar
• Ahlskog JE, Uitti RJ. Rasagiline, Parkinson neuroprotection, and delayed-start trials: still no satisfaction? Neurology 74(14), 1143–1148 (2010).
   PubMed Web of Science ®Google Scholar
• Booij J, Berendse HW. Monitoring therapeutic effects in Parkinson’s disease by serial imaging of the nigrostriatal dopaminergic pathway. J. Neurol. Sci. 310(1–2), 40–43 (2011).
   PubMed Web of Science ®Google Scholar